|
JPS62153300A
(ja)
|
1985-12-26 |
1987-07-08 |
Teijin Ltd |
ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5326856A
(en)
|
1992-04-09 |
1994-07-05 |
Cytogen Corporation |
Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
EP1323346B1
(en)
|
1995-01-17 |
2006-06-28 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6725230B2
(en)
|
2000-07-18 |
2004-04-20 |
Aegis Analytical Corporation |
System, method and computer program for assembling process data of multi-database origins using a hierarchical display
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US6992234B2
(en)
|
2000-11-06 |
2006-01-31 |
The Jackson Laboratory |
FcRn-based therapeutics for the treatment of auto-immune disorders
|
|
CA2467781C
(en)
|
2000-11-20 |
2014-09-23 |
Canadian Blood Services |
Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
EP2180044A1
(en)
|
2001-08-03 |
2010-04-28 |
GlycArt Biotechnology AG |
Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
DE60334453D1
(de)
|
2002-05-30 |
2010-11-18 |
Macrogenics Inc |
Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
|
|
EP1534335B9
(en)
|
2002-08-14 |
2016-01-13 |
Macrogenics, Inc. |
Fcgammariib-specific antibodies and methods of use thereof
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DE60334141D1
(de)
|
2002-10-15 |
2010-10-21 |
Facet Biotech Corp |
VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
|
|
EP1588166A4
(en)
|
2003-01-09 |
2007-06-27 |
Macrogenics Inc |
VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
WO2004062619A2
(en)
|
2003-01-13 |
2004-07-29 |
Macrogenics, Inc. |
SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF
|
|
RU2358763C2
(ru)
*
|
2003-02-10 |
2009-06-20 |
Элан Фармасьютикалз, Инк. |
Композиции иммуноглобулина и способ их получения
|
|
US7662928B2
(en)
|
2003-08-08 |
2010-02-16 |
The Research Foundation Of State University Of New York |
Anti-FcRn antibodies for treatment of auto/allo immune conditions
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
WO2006035600A1
(ja)
|
2004-09-30 |
2006-04-06 |
Brother Kogyo Kabushiki Kaisha |
無線タグ通信装置、無線タグ、無線通信システム、及び無線通信方法
|
|
BRPI0606867A2
(pt)
|
2005-01-28 |
2009-07-21 |
Wyeth Corp |
formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
|
|
CA2606378A1
(en)
|
2005-04-29 |
2006-11-09 |
The Jackson Laboratory |
Fcrn antibodies and uses thereof
|
|
WO2006130834A2
(en)
|
2005-05-31 |
2006-12-07 |
Board Of Regents, The University Of Texas System |
IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
MX2009012343A
(es)
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
|
CN101835802B
(zh)
|
2007-06-01 |
2014-04-09 |
马里兰大学巴尔的摩分校 |
免疫球蛋白恒定区Fc受体结合剂
|
|
US8108517B2
(en)
|
2007-11-27 |
2012-01-31 |
Umber Systems |
System and method for collecting, reporting and analyzing data on application-level activity and other user information on a mobile data network
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
US20110059091A1
(en)
|
2008-02-04 |
2011-03-10 |
Xiao-Jia Chang |
Inhibitors of oncogenic isoforms and uses thereof
|
|
BRPI0910622A2
(pt)
|
2008-04-25 |
2020-03-10 |
Dyax Corp. |
ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
|
|
WO2010014909A1
(en)
|
2008-08-01 |
2010-02-04 |
Syntonix Pharmaceuticals, Inc. |
Immunomodulatory peptides
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
MY173526A
(en)
|
2009-03-25 |
2020-01-31 |
Genentech Inc |
Novel anti-?5?1 antibodies and uses thereof
|
|
MX2012003282A
(es)
|
2009-09-17 |
2012-04-30 |
Baxter Healthcare Sa |
Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
MX2012007676A
(es)
|
2009-12-29 |
2012-08-03 |
Hoffmann La Roche |
Nueva formulacion de anticuerpo.
|
|
KR102014554B1
(ko)
|
2011-06-02 |
2019-08-26 |
다이액스 코포레이션 |
Fc 수용체 결합 단백질
|
|
CA2853637C
(en)
|
2011-10-26 |
2023-04-04 |
Novartis Ag |
Anti-canine cd20 monoclonal antibodies and methods of use
|
|
EP2780463A4
(en)
|
2011-11-18 |
2015-07-01 |
Merck Sharp & Dohme |
FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
|
|
KR102041412B1
(ko)
|
2011-12-30 |
2019-11-11 |
한미사이언스 주식회사 |
면역글로불린 Ｆｃ 단편 유도체
|
|
US20150125449A1
(en)
|
2012-05-10 |
2015-05-07 |
Zymeworks Inc. |
Single-Arm Monovalent Antibody Constructs and Uses Thereof
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
EP3578660A1
(en)
|
2012-07-05 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Expression and secretion system
|
|
ES2660912T3
(es)
|
2013-03-15 |
2018-03-26 |
Affibody Ab |
Nuevos polipéptidos
|
|
KR101815265B1
(ko)
|
2013-06-20 |
2018-01-04 |
한올바이오파마주식회사 |
FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
AU2014348552A1
(en)
|
2013-11-13 |
2016-06-02 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
|
JP6620094B2
(ja)
|
2013-11-26 |
2019-12-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． |
免疫応答を調節するための組成物および方法
|
|
CN112142843B
(zh)
|
2013-12-24 |
2024-10-18 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
|
SI3193930T1
(sl)
|
2014-09-17 |
2019-10-30 |
Affibody Ab |
Novi polipeptidi
|
|
KR20250052465A
(ko)
|
2015-01-30 |
2025-04-18 |
모멘타 파머슈티컬스 인코포레이티드 |
ＦｃＲｎ 항체 및 이의 사용 방법
|
|
MY188761A
(en)
*
|
2015-03-09 |
2021-12-29 |
Argenx Bvba |
Method of reducing serum levels of fc-containing agents using fcrn antagonists
|
|
ES2956662T3
(es)
|
2015-05-12 |
2023-12-26 |
Syntimmune Inc |
Anticuerpos anti-FcRn humanizados con afinidad madurada
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7118884B2
(ja)
|
2015-07-17 |
2022-08-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
|
|
CN106957365B
(zh)
|
2016-01-11 |
2021-03-16 |
上海交通大学 |
一种单克隆抗体FnAb8及其应用
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
CA3032415A1
(en)
|
2016-07-29 |
2018-02-01 |
Momenta Pharmaceuticals, Inc. |
Fcrn antibodies and methods of use thereof
|
|
GB201618424D0
(en)
*
|
2016-11-01 |
2016-12-14 |
Argenix Bvba |
Treatment of antibody mediated disease
|
|
US12240875B2
(en)
|
2017-12-08 |
2025-03-04 |
argenx BV |
Use of FCRN antagonists for treatment of generalized myasthenia gravis
|
|
KR102904658B1
(ko)
|
2017-12-13 |
2025-12-29 |
모멘타 파머슈티컬스 인코포레이티드 |
FcRn 항체 및 이의 사용 방법
|
|
CA3101462A1
(en)
|
2018-06-08 |
2019-12-12 |
Argenx Bvba |
Compositions and methods for treating immune thrombocytopenia
|
|
EP3866785A1
(en)
|
2018-10-15 |
2021-08-25 |
Merck Patent GmbH |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
|
US20220002402A1
(en)
|
2018-11-06 |
2022-01-06 |
Immunovant Sciences Gmbh |
Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
WO2020236695A1
(en)
|
2019-05-17 |
2020-11-26 |
Alexion Pharmaceuticals, Inc. |
Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
|
|
CN114126647A
(zh)
|
2019-06-07 |
2022-03-01 |
阿尔金克斯有限公司 |
适用于皮下施用的FcRn抑制剂的药物制剂
|
|
EP4007605A4
(en)
|
2019-08-01 |
2023-08-16 |
Momenta Pharmaceuticals, Inc. |
ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF
|
|
BR112022013554A2
(pt)
|
2020-01-08 |
2022-09-06 |
argenx BV |
Métodos para tratar distúrbios do pênfigo
|
|
BR112022021392A2
(pt)
|
2020-04-22 |
2022-12-06 |
Igm Biosciences Inc |
Moléculas de ligação multiméricas de agonista de pd-1
|
|
IL302516A
(en)
|
2020-11-06 |
2023-07-01 |
Janssen Biotech Inc |
FCRN antibodies and methods of using them
|
|
WO2023012515A2
(en)
|
2021-08-02 |
2023-02-09 |
argenx BV |
Subcutaneous unit dosage forms
|
|
JP2025504815A
(ja)
|
2022-01-17 |
2025-02-19 |
アルジェニクス ビーブイ |
自己抗体媒介性疾患を有する患者を治療するための方法
|
|
KR20240151809A
(ko)
|
2022-02-21 |
2024-10-18 |
아르젠엑스 비브이 |
Fcrn 길항제를 사용하여 근염을 치료하는 방법
|
|
IL316524A
(en)
|
2022-04-26 |
2024-12-01 |
argenx BV |
Methods for treating bullous pemphigoid using FCRN antagonists
|
|
CA3258000A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
|
|
EP4615481A1
(en)
|
2022-11-07 |
2025-09-17 |
argenx BV |
Methods for treating lupus nephritis using fcrn antagonists
|
|
TW202428303A
(zh)
|
2022-11-07 |
2024-07-16 |
比利時商阿根思公司 |
使用ｆｃｒｎ拮抗劑治療原發性膜性腎病變之方法
|
|
KR20250109198A
(ko)
|
2022-11-14 |
2025-07-16 |
아르젠엑스 비브이 |
Fcrn 길항제 분자 및 이의 사용 방법
|
|
AR131560A1
(es)
|
2023-01-06 |
2025-04-09 |
argenx BV |
Métodos para tratar pots mediante el uso de antagonistas de fcrn
|